Key Highlights
- Brian Armstrong’s biotech firm NewLimit secured $435 million in new financing, elevating its valuation to $3.1 billion
- The company’s worth has increased more than threefold from its previous valuation of under $1 billion recorded less than twelve months ago
- NewLimit specializes in cellular age reversal using epigenetic reprogramming technology, though it has yet to launch any commercial products
- Human clinical testing is scheduled to commence in 2027, with initial focus on treating alcohol-induced liver disease
- Despite Armstrong’s crypto background, NewLimit operates as a conventional biotech investment with zero blockchain integration
The Coinbase CEO who made billions in cryptocurrency is now channeling substantial resources into a radically different venture: reversing the aging process at the cellular level.
NewLimit, the Bay Area-based biotechnology firm co-launched by Armstrong, has successfully completed a $435 million financing round. This injection of capital brings the company’s post-money worth to $3.1 billion — representing more than a three-fold jump from the valuation assigned during its Series B financing completed under twelve months prior.
Armstrong established NewLimit in 2022 with partners Blake Byers and Jacob Kimmel. Kimmel brings experience from Calico, Alphabet’s longevity-focused research division.
The scientific foundation rests on epigenetic reprogramming principles. During the aging process, human cells retain their genetic code but progressively lose the capacity to interpret it as effectively as in younger years. NewLimit is engineering pharmaceutical compounds that employ transcription factors as molecular instruments to restore youthful gene expression patterns in aging cells.
The delivery mechanism relies on lipid nanoparticles, the identical foundational technology that powers mRNA-based COVID-19 vaccines.
Current Research Status
NewLimit has yet to administer its therapeutic candidates to human subjects. The organization has completed preclinical research, encompassing human cell screening protocols and animal model studies, though human experimentation remains on the horizon.
The strategy involves submitting its inaugural clinical trial application in 2027, concentrating on alcohol-related liver pathology. The company’s primary research targets include hepatic tissue, immune system components, and vascular networks.
The $3.1 billion market valuation rests exclusively on preclinical experimental data.
NewLimit pursues what scientists term partial epigenetic reprogramming. The objective involves a controlled cellular age reset — avoiding complete reversion to a stem-cell state, which presents potential cancer risks.
The financing trajectory demonstrates rapidly accelerating investor enthusiasm. NewLimit secured $130 million in Series B funding during May 2025, with Kleiner Perkins serving as lead investor. The latest round, finalized this past Friday, represents more than triple that amount in a single closing.
The Cryptocurrency Connection Explained
The straightforward answer: there isn’t one. NewLimit operates without any cryptocurrency token, blockchain infrastructure, or decentralized product offerings. Armstrong’s responsibilities at Coinbase remain distinct from his involvement with NewLimit.
For those tracking Armstrong primarily due to his leadership position at one of the planet’s premier cryptocurrency platforms, this represents a conventional biotech venture capital opportunity.
The capacity to secure $435 million in funding ahead of any human clinical data indicates substantial institutional confidence. Kleiner Perkins, which spearheaded the previous financing round, maintains its investment position.
NewLimit now enters a expanding field of longevity-focused ventures supported by technology industry billionaires. The subsequent critical benchmark arrives when the organization files its clinical trial documentation, anticipated in 2027.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
